Audent Global Asset Management’s iShares Biotechnology ETF IBB Stock Holding History
Bought
Maintained
Sold
Other funds holding IBB
Audent Global Asset Management's IBB Position: Q3 2026 in Review
Audent Global Asset Management reduced its iShares Biotechnology ETF (IBB) stake by 0.23% in Q3 2026, selling an estimated $4.21K and leaving 9,146 shares worth $1.93M. The position accounts for 2.09% of the portfolio, ranked #19.
Audent Global Asset Management first reported a position in IBB in Q4 2021 and has held it in 20 quarters since. The position peaked at $8.15M in Q4 2021. 1,026 funds tracked by Wall St. Rank hold IBB as of Q3 2026.
- Audent Global Asset Management held 9,146 shares of iShares Biotechnology ETF worth $1.93M as of Q3 2026.
- Audent Global Asset Management sold 21 iShares Biotechnology ETF shares in Q3 2026, an estimated $4.21K.
- iShares Biotechnology ETF made up 2.09% of Audent Global Asset Management's portfolio in Q3 2026, its #19 holding.
- Audent Global Asset Management first reported a position in iShares Biotechnology ETF in Q4 2021 and has held it in 20 quarters since.
- Audent Global Asset Management's iShares Biotechnology ETF position peaked at $8.15M in Q4 2021.
- 1,026 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2026.
Based on Audent Global Asset Management's 13F filing for Q3 2026, filed 12 Nov 2026.